JPRN-UMIN000028492已完成未知
Evaluation of 0.25% AGN-229666 ophthalmic solution compared to vehicle or olopatadine in the conjunctival allergen challenge (CAC) model of allergic conjunctivitis - Evaluation of 0.25% AGN-229666 ophthalmic solution compared to vehicle or olopatadine in the conjunctival allergen challenge (CAC) model of allergic conjunctivitis
适应症
试验速览
- 阶段
- 未知
- 状态
- 已完成
- 入组人数
- 240
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 20years-old 至 ot applicable（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •1) Have a history of allergic hypersensitivity to any compound or chemical class related to the investigational drug being studied or its excipients used in this trial 2) Have previous participation in a clinical trial with AGN-229666 3) Have presence of any ocular condition that could affect the patient's safety or trial parameters 4) Have known history of vernal keratoconjunctivitis and/or atopic keratoconjunctivitis 5) Have had ocular surgical intervention and/or a history of refractive surgery 6) Have a known history of retinal detachment, diabetic retinopathy, or progressive retinal disease 7) Have the presence of an active ocular infection or preauricular lymphadenopathy, or positive history of an ocular herpetic infection 8) Have any uncontrolled systemic disease 9) Have history of status asthmaticus, persistent moderate or severe asthma, or moderate to severe allergic asthmatic reactions to study allergen(s) 10) Manifest signs or symptoms of clinically active allergic conjunctivitis 11) Be a female who is pregnant or nursing, or a person who is planning a pregnancy 12) Be a person not using a reliable means of contraception 13) Have a use of disallowed medications during the appropriate pre-study washout period or anticipated use during the study 14) Have a use of depot corticosteroids within 6 months or anticipated use during the study 15) Have planned surgery (ocular or systemic) during the study period or within 30 days after completion 16) Be currently enrolled in an investigational drug or device study or have had administration of investigational drug in such a study within 16 weeks of entry into this study
研究者
相似试验
已完成
1 期
Safety and Efficacy of AGN 210669 Ophthalmic Solution in Patients With Ocular Hypertension or Primary Open-Angle GlaucomaGlaucomaOcular HypertensionNCT00809848Allergan172
已完成
2 期
Safety and Efficacy of AGN-210961 Ophthalmic Solution Compared With Bimatoprost Ophthalmic Solution in Patients With Glaucoma or Ocular HypertensionOcular HypertensionPrimary Open-Angle GlaucomaNCT01110499Allergan163
已完成
3 期
AGN-229666 Ophthalmic Solution for the Treatment of Seasonal or Perennial Allergic ConjunctivitisConjunctivitis, AllergicNCT02082262Allergan140
已完成
2 期
Safety and Efficacy of AGN-210669 Ophthalmic Solution Compared With Bimatoprost Ophthalmic Solution in Patients With Open-Angle Glaucoma or Ocular HypertensionGlaucoma, Open-AngleOcular HypertensionNCT01291108Allergan125
终止
3 期
Topical Ophthalmic AGN-195263 for the Treatment of Evaporative Dry EyeDry Eye SyndromesNCT02965846Allergan43